Lv1
32 积分 2024-03-26 加入
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
1小时前
已完结
NASP modulates histone turnover to drive PARP inhibitor resistance
2个月前
已完结
Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer
2个月前
已完结
Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib
2个月前
已完结
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
2个月前
已完结
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
2个月前
已完结
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
2个月前
已完结
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2个月前
已完结
Dihydroartemisinin breaks the immunosuppressive tumor niche during cisplatin treatment in Hepatocellular carcinoma
3个月前
已完结
Dihydroartemisinin increases gemcitabine therapeutic efficacy in ovarian cancer by inducing reactive oxygen species
3个月前
已完结
皖公网安备34019202002308
